EU Accuses Teva Of Misusing IP To Block Rival MS Drugs
Europe's competition enforcer accused Teva Pharmaceuticals on Monday of stifling competition for its branded multiple sclerosis treatment by artificially extending patent protections and spreading misinformation about rival products....To view the full article, register now.
Already a subscriber? Click here to view full article